Here is our latest publication, titled Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE).
Discover why there is a crucial need to decipher mechanisms underlying sensitivity / resistance to cancer immunotherapies which can ultimately lead to the identification of novel therapeutic targets and how to achieve it.
Our data illustrated here through DC differentiation and mixed leukocyte reaction assays show that adenosine-mediated suppression results in the generation of phenotypically and functionally dysregulated DCs, and that this process is relieved by adenosine receptor antagonists.
Discover our latest publication, titled CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells.
We have fully set up and characterized a syngeneic Lewis LLC1 mouse model for preclinical studies of novel therapeutic agents and anti-cancer strategies.
In a recent collaborative work (1) supervised by Pr A. Italiano and published in Nature Cancer (2), we highlighted that the presence of mature tertiary lymphoid structures (mTLS) – a structure of prominent B cell follicles and follicular dendritic cells adjoined to a CD4/CD8 T cell-containing zone - is a new predictive biomarker for response for immune checkpoint blockers.
Read our latest publication, titled Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1.
Read our latest publication, titled Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE)
Read our latest paper, titled Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.
To assess whether or not the tumor immune contexture was predictive of response to the Avelumab-Regorafenib combination regimen, Explicyte developed and ran a multiplexed immunohistofluorescence panel, in addition to Dapi.
It becomes primordial to benefit from a technological platform that allows to deal with the tumor biology complexity/heterogeneity and get specific investigations in compartments of interest (e.g. tumor vs stroma). Thanks to the GeoMx platform (Nanostring Inc.), the Digital Spatial Profiling revolution has started.